Abstract
Nuclear magnetic resonance (NMR) spectroscopy is being used to determine the concentrations of very low‐density lipoprotein (VLDL), low‐density lipoprotein (LDL), and high‐density lipoprotein (HDL) subclasses of different size. These subclasses have unequal associations with coronary heart disease. Nuclear magnetic resonance distinguishes among the subclasses on the basis of slight differences in the spectral properties of the lipids carried within the particles, which vary according to the diameter of the phospholipid shell. Studies using NMR spectroscopy have shown that individuals with elevated triglycerides are likely to have higher‐risk lipoprotein subclass profiles. Triglyceride‐rich lipoproteins drive the metabolic reactions that produce LDL of abnormal size and cholesterol content. The quantities of these abnormal LDL particles and the associated risk of coronary heart disease are underestimated by conventional cholesterol measurements. Nuclear magnetic resonance spectroscopy measures lipoprotein subclasses directly and efficiently, and produces information that may improve the assessment and management of cardiovascular disease risk.
Keywords: coronary heart disease, very low‐density lipoproteins, low‐density lipoproteins, high‐density lipoproteins, nuclear magnetic resonance spectroscopy, lipoprotein subclasses
Full Text
The Full Text of this article is available as a PDF (939.2 KB).
References
- 1. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM: Low‐density lipoprotein subclass patterns and risk of myocardial infarction. J Am Med Assoc 1998; 260: 1917–1921 [PubMed] [Google Scholar]
- 2. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després J‐P: Small, dense low‐density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: Prospective results from the Québec Cardiovascular Study. Circulation 1997; 95: 69–75 [DOI] [PubMed] [Google Scholar]
- 3. Krauss RM: Relationship of intermediate‐ and low‐density lipoprotein subspecies to risk of coronary artery disease. Am Heart J 1987; 113: 578–582 [DOI] [PubMed] [Google Scholar]
- 4. Wilson HN, Patel JC, Russe D, Skinner ER: Alterations in the concentration of an apolipoprotein E‐containing subfraction of plasma high density lipoproteinin coronary heart disease. Clin Chim Acta 1993; 220: 175–187 [DOI] [PubMed] [Google Scholar]
- 5. Johansson J, Carlson LA, Landou C, Hamsten A: High‐density lipoproteins and coronary atherosclerosis: A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 1991; 11: 174–182 [DOI] [PubMed] [Google Scholar]
- 6. Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA: Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18: 1046–1053 [DOI] [PubMed] [Google Scholar]
- 7. Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM: Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 1992; 38: 1632–1638 [PubMed] [Google Scholar]
- 8. Otvos JD: Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy In Handbook of Lipoprotein Testing. (Eds. Rifai N, Warnick G, Dominiczak MH.), p. 497–508. Washington DC: AACC Press; 1997. [Google Scholar]